



P&T Committee Meeting Minutes

Subject:	Louisiana Department of Health Medicaid Pharmaceutical and Therapeutic Committee Meeting
Location:	628 North Fourth Street Baton Rouge, LA Bienville Building Room 118 And Virtual Zoom Webinar: https://magellanhealth.zoom.us/webinar/register/WN_B8OKBzKUQuytiGZlurm1FA
Date:	November 4, 2022
Members Present:	▪ Dr. James Hussey ▪ Dr. Scott Black ▪ Dr. Charles C. Coleman ▪ Dr. Tammy D. Hart ▪ Dr. Jill Comeau ▪ Dr. Mary C. Raven ▪ Dr. Julio E. Figueroa ▪ Dr. David M. Mushatt ▪ Ben Orlando, RPh
LDH Pharmacy Program Staff Present:	▪ Jennie Stelly, RPh ▪ Sue Fontenot, RPh ▪ Melwyn Wendt, PharmD ▪ Haley Williams ▪ Gabrielle Johnson-Stewart ▪ Rachel Broussard, RPh ▪ Kimberly Sullivan
Contractors Present:	▪ Hind Douiki, PharmD, Magellan Medicaid Administration ▪ Kara Delaney, PharmD, Magellan Medicaid Administration ▪ Rachel Y. Torres, Certified Court Reporter

Others Present: Presenters are listed in the minutes and sign in sheets and others in attendance from LDH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.

Call to Order

Mr. Ben Orlando, Vice Chairman, called the meeting to order at or around 9:03 a.m. after a quorum was reached with 9 members. He stated that this meeting will be conducted in compliance with the Open Meetings Law.

Parliamentary Business

- A. Introduction of Members/Roll Call.** Committee members, LDH staff, and contractors introduced themselves.
- B. Election of Chairman and Co-Chairman.** Dr. Comeau nominated Ben Orlando as Chair; the latter accepted the nomination. All members voted in favor for the Chair nomination. Ben Orlando nominated Dr. Comeau for Vice Chair of the committee. All members voted in favor for the Vice Chair nomination.
- C. P & T Bylaws – Proposed Amendments.** Mr. Orlando indicated that due to COVID-19, the committee was not able to vote on some changes that need to be made.

The first change is the deletion of the word “hospitals” from the Department name.

The second change is the total number of committees members is being changed from 21 to 15. In addition, some wording was changed to include demographic stipulations and some terminologies that specified the pharmacology experience have been deleted.

The third change is the quorum will be composed of a majority instead of a quorum within each service or each physician category,

Mr. Orlando went over a few more minor changes.

Dr. Figueroa made a motion to accept the changes in the bylaws as presented; all committee members voted in favor of those changes.

- D. Approval of April 26, 2019 Meeting Minutes.** Mr. Orlando asked the members if they had any questions about the April 26, 2019 P&T meeting minutes. Dr. Figueroa made a motion to accept the minutes; Dr. Black seconded it. All members voted to approve the minutes.
- E. Approval of May 6, 2022 Meeting Minutes.** Dr. Figueroa made a motion to accept the minutes; Dr. Black seconded it. All members voted to approve the minutes.

Ethics Reminders

Ms. Williams went over several sections of the code of ethics. Members are bound by the governmental code of ethics. All committee members are required to complete the online ethics training every calendar year.

Reports

- A. PDL Reflecting Spring 2022 Recommendations.** Dr. Wendt explained that for a drug to be covered by Medicaid, its manufacturer has to sign a CMS agreement and provide a discount to the State in a form of a rebate, often referred to as a federal rebate. Dr. Wendt also stated the PDL Reflecting Spring 2022 Recommendations is the current PDL that was based on the last meeting, with the recommendation of which drugs are preferred and which drugs require prior authorization, with the imbedded criteria included.

New Business

A. Explanation of TOP\$, Monographs and Cost Sheets

Dr. Douiki provided an overview of the TOP\$ supplemental rebate pool that Louisiana Medicaid participates in. She presented information about clinical and financial components of the recommendation process. Dr. Douiki also summarized the supplemental rebate process. She indicated to the members that they should have received clinical documents, in the form of Therapeutic Class Reviews or New Drug Updates...etc. The committee members should also have cost sheets which include relative values, rather than actual numbers, in order to comply with the privacy laws regarding rebates.

- B. Therapeutic Class Reviews of Fall Drug Classes/Drug Manufacturer Testimony.** In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing	Drug/Issue
Ashley Castello	Louisiana Hemophilia Foundation	Hemophilia Drug Class
Jennifer	Tulane University Medical School	Hemophilia Drug Class
**NOTE: Names of speakers who were present and yielded their time back were not captured.		

Alzheimer's Agents

Dr. Figueroa made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- DONEPEZIL ODT (ORAL)
- DONEPEZIL TABLET (ORAL)
- MEMANTINE TABLET (AG) (ORAL)
- MEMANTINE TABLET (ORAL)
- RIVASTIGMINE (AG) (TRANSDERM.)

- RIVASTIGMINE (TRANSDERM.)

Anthelmintics

Dr. Figueroa made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ALBENDAZOLE (ORAL)
- EMVERM (ORAL)
- IVERMECTIN (ORAL)
- PRAZQUANTEL (ORAL)

Anti-Allergens, Oral

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- None (all products in this class are recommended NPD)

Anticonvulsants

Dr. Figueroa made the motion to accept. Dr. Hussey seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- | | |
|--|---|
| • APTIOM (ORAL) | • LAMOTRIGINE TABLET (ORAL) |
| • BANZEL SUSPENSION (ORAL) | • LAMOTRIGINE XR (ORAL) |
| • BANZEL TABLET (ORAL) | • LEVETIRACETAM ER (ORAL) |
| • BRIVIACT SOLUTION (ORAL) | • LEVETIRACETAM SOLUTION (ORAL) |
| • BRIVIACT TABLET (ORAL) | • LEVETIRACETAM TABLETS (ORAL) |
| • CARBAMAZEPINE CHEWABLE TABLET (ORAL) | • NAYZILAM (NASAL) |
| • CARBAMAZEPINE TABLET (ORAL) | • OXCARBAZEPINE TABLETS (ORAL) |
| • CARBATROL (ORAL) | • OXTELLAR XR (ORAL) |
| • CELONTIN (ORAL) | • PHENOBARBITAL ELIXIR (ORAL) |
| • CLOBAZAM SUSPENSION (ORAL) | • PHENOBARBITAL TABLET (ORAL) |
| • CLOBAZAM TABLET (ORAL) | • PHENYTOIN CAPSULE (ORAL) |
| • CLONAZEPAM (ORAL) | • PHENYTOIN CHEWABLE TABLET (ORAL) |
| • CLONAZEPAM ODT (ORAL) | • PHENYTOIN EXT CAPSULE (GENERIC PHENYTEK) (ORAL) |
| • DEPAKOTE SPRINKLE (ORAL) | • PHENYTOIN SUSPENSION (AG) (ORAL) |
| • DIACOMIT CAPSULE (ORAL) | • PHENYTOIN SUSPENSION (ORAL) |
| • DIACOMIT POWDER PACK (ORAL) | • PRIMIDONE (ORAL) |
| • DIASTAT (RECTAL) | |

- DIASTAT ACUDIAL (RECTAL)
- DIAZEPAM (AG) (RECTAL)
- DIAZEPAM DEVICE (AG) (RECTAL)
- DILANTIN 30 MG CAPSULE (ORAL)
- DIVALPROEX ER (ORAL)
- DIVALPROEX TABLET (ORAL)
- EPIDIOLEX (ORAL)
- ETHOSUXIMIDE CAPSULE (AG) (ORAL)
- ETHOSUXIMIDE CAPSULE (ORAL)
- ETHOSUXIMIDE SYRUP (ORAL)
- FELBAMATE SUSPENSION (ORAL)
- FELBAMATE TABLET (ORAL)
- FELBATOL TABLET (ORAL)
- FYCOMPA SUSPENSION (ORAL)
- FYCOMPA TABLET (ORAL)
- LACOSAMIDE SOLUTION (ORAL)
- LACOSAMIDE TABLET (ORAL)
- LAMOTRIGINE DISPERSIBLE TABLET (ORAL)
- LAMOTRIGINE ODT (ORAL)
- SABRIL POWDER PACK (ORAL)
- SABRIL TABLET (ORAL)
- TEGRETOL XR (ORAL)
- TOPIRAMATE ER (QUDEXY) (AG) (ORAL)
- TOPIRAMATE SPRINKLE (ORAL)
- TOPIRAMATE TABLETS (ORAL)
- TRILEPTAL SUSPENSION (ORAL)
- VALPROIC ACID CAPSULE (ORAL)
- VALPROIC ACID SOLUTION (ORAL)
- VALTOCO (NASAL)
- XCOPRI TABLET (ORAL)
- XCOPRI TITRATION PAK (ORAL)
- ZONISAMIDE (ORAL)

Antidepressants, Other

Dr. Hussey made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- BUPROPION (ORAL)
- BUPROPION SR (ORAL)
- BUPROPION XL (ORAL)
- MIRTAZAPINE ODT (ORAL)
- MIRTAZAPINE TABLET (ORAL)
- TRAZODONE (ORAL)
- VENLAFAXINE (ORAL)
- VENLAFAXINE ER CAPSULES (ORAL)

Antidepressants, SSRI

Dr. Hussey made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- CITALOPRAM SOLUTION (ORAL)
- CITALOPRAM TABLET (ORAL)
- ESCITALOPRAM TABLET (ORAL)
- FLUOXETINE CAPSULE (ORAL)
- FLUOXETINE SOLUTION (ORAL)
- FLUVOXAMINE (ORAL)
- PAROXETINE TABLET (ORAL)
- SERTRALINE CONC (ORAL)
- SERTRALINE TABLET (ORAL)

Antihistamines, Minimally Sedating

Dr. Black made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- CETIRIZINE SOLUTION (ORAL)
- CETIRIZINE SOLUTION OTC (ORAL)
- CETIRIZINE TABLETS OTC (ORAL)
- CETIRIZINE-D OTC (ORAL)
- LEVOCETIRIZINE TABLETS (ORAL)
- LEVOCETIRIZINE TABLETS OTC (ORAL)
- LORATADINE ODT OTC (ORAL)
- LORATADINE SOLUTION OTC (ORAL)
- LORATADINE TABLETS OTC (ORAL)
- LORATADINE-D OTC (ORAL)

Antihypertensives, Sympatholytics

Dr. Figueroa made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- CATAPRES-TTS (TRANSDERM)
- CLONIDINE (ORAL)
- CLONIDINE (TRANSDERM)
- GUANFACINE (ORAL)
- METHYLDOPA (ORAL)

Antihyperuricemics

Dr. Mushatt made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ALLOPURINOL (ORAL)
- COLCHICINE TABLET (AG) (ORAL)
- COLCHICINE TABLET (ORAL)
- FEBUXOSTAT (ORAL)
- PROBENECID (ORAL)
- PROBENECID / COLCHICINE (ORAL)

Antiparkinson's Agents

Dr. Coleman made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- AMANTADINE CAPSULE (ORAL)
- AMANTADINE SYRUP (ORAL)
- BENZTROPINE (ORAL)
- CARBIDOPA / LEVODOPA (ORAL)
- CARBIDOPA / LEVODOPA ER (ORAL)
- CARBIDOPA/LEVODOPA/ENTACAPONE (ORAL)
- PRAMIPEXOLE (ORAL)
- ROPINIROLE (ORAL)
- SELEGILINE TABLET (ORAL)
- TRIHEXYPHENIDYL ELIXIR (ORAL)
- TRIHEXYPHENIDYL TABLET (ORAL)

Antipsoriatics, Oral

Dr. Figueroa made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ACITRETIN (AG) (ORAL)
- ACITRETIN (ORAL)

Antipsoriatics, Topical

Dr. Mushatt Figueroa made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- CALCIPOTRIENE CREAM (TOPICAL)
- CALCIPOTRIENE SOLUTION (TOPICAL)

Antipsychotics

Dr. Coleman made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- | | |
|---------------------------------------|---------------------------------|
| • ABILIFY MAINTENA (INTRAMUSC.) | • LATUDA (ORAL) |
| • AMITRIPTYLINE / PERPHENAZINE (ORAL) | • LOXAPINE (ORAL) |
| • ARIPIPRAZOLE TABLET (ORAL) | • OLANZAPINE ODT (ORAL) |
| • ARISTADA (INTRAMUSC) | • OLANZAPINE TABLET (ORAL) |
| • ARISTADA INITIO (INTRAMUSC) | • PERPHENAZINE (ORAL) |
| • CHLORPROMAZINE (ORAL) | • PERSERIS (SUBCUTANEOUS) |
| • CLOZAPINE (ORAL) | • PIMOZIDE (ORAL) |
| • FLUPHENAZINE DECANOATE (INJECTION) | • QUETIAPINE ER (ORAL) |
| • FLUPHENAZINE TABLET (ORAL) | • QUETIAPINE TABLETS (ORAL) |
| • GEODON (INTRAMUSC) | • RISPERDAL CONSTA (INTRAMUSC.) |
| • HALOPERIDOL (ORAL) | • RISPERIDONE SOLUTION (ORAL) |
| • HALOPERIDOL DECANOATE (INJECTION) | • RISPERIDONE TABLET (ORAL) |
| • HALOPERIDOL LACTATE (INJECTION) | • THIORIDAZINE (ORAL) |
| • HALOPERIDOL LACTATE CONC (ORAL) | • THIOTHIXENE (ORAL) |
| • INVEGA HAFYERA (INTRAMUSC) | • TRIFLUOPERAZINE (ORAL) |
| • INVEGA SUSTENNA (INTRAMUSC) | • VRAYLAR (ORAL) |
| • INVEGA TRINZA (INTRAMUSC) | • ZIPRASIDONE (INTRAMUSC) |
| | • ZIPRASIDONE CAPSULE (ORAL) |

Anxiolytics

Dr. Mushatt made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ALPRAZOLAM TABLET (ORAL)
- BUSPIRONE (ORAL)
- LORAZEPAM TABLET (ORAL)

Bile Salts

Dr. Figueroa made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- URSODIOL TABLET (ORAL)
- URSODIOL 300 MG CAPSULE (ORAL)

Botulinum Toxins

Dr. Figueroa made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- BOTOX (INTRAMUSC)
- DYSPORT (INTRAMUSC)

Bronchodilators, Beta Agonist

Dr. Mushatt made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ALBUTEROL HFA (PROAIR) (AG) (INHALATION)
- ALBUTEROL HFA (PROAIR) (INHALATION)
- ALBUTEROL HFA (PROVENTIL) (AG) (INHALATION)
- ALBUTEROL HFA (PROVENTIL) (INHALATION)
- ALBUTEROL HFA (VENTOLIN) (AG) (INHALATION)
- ALBUTEROL NEB SOLN 0.63, 1.25 MG (AG) (INHALATION)
- ALBUTEROL NEB SOLN 0.63, 1.25 MG (INHALATION)
- ALBUTEROL NEB SOLN 100 MG/20 ML (INHALATION)
- ALBUTEROL NEB SOLN 2.5 MG/0.5 ML (INHALATION)
- ALBUTEROL NEB SOLN 2.5 MG/3 ML (INHALATION)
- ALBUTEROL SYRUP (ORAL)
- PROAIR HFA (INHALATION)
- PROVENTIL HFA (INHALATION)
- SEREVENT (INHALATION)
- VENTOLIN HFA (INHALATION)

Colony Stimulating Factors

Dr. Mushatt made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- FULPHILA (SUBCUTANEOUS)
- NEUPOGEN DISP SYRIN (INJECTION)
- NEUPOGEN VIAL (INJECTION)
- NYVEPRIA (SUBCUTANEOUS)

COPD Agents

Dr. Coleman made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ANORO ELLIPTA (INHALATION)
- ATROVENT HFA (INHALATION)
- COMBIVENT RESPIMAT (INHALATION)
- IPRATROPIUM / ALBUTEROL (INHALATION)
- IPRATROPIUM NEBULIZER (INHALATION)
- SPIRIVA (INHALATION)
- STIOLTO RESPIMAT (INHALATION)

Cytokine and CAM Antagonists

Dr. Figueroa made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ENBREL KIT (INJECTION)
- ENBREL MINI CARTRIDGE (SUBCUTANE.)
- ENBREL PEN (INJECTION)
- ENBREL SYRINGE (INJECTION)
- ENBREL VIAL (SUBCUTANEOUS)
- HUMIRA KIT (INJECTION)
- HUMIRA PEN KIT (INJECTION)
- OTEZLA (ORAL)

Emollients

Dr. Figueroa made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- AMMONIUM LACTATE CREAM/LOTION (TOPICAL)

Enzyme Replacement, Gaucher Disease

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- None (all products in this class are recommended NPD)

Epinephrine, Self-Injected

Dr. Coleman made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- EPINEPHRINE 0.15 MG (EPIPEN JR) (AG) (INJECTION)
- EPINEPHRINE 0.15 MG (EPIPEN JR) (INJECTION)
- EPINEPHRINE 0.3 MG (EPIPEN) (AG) (INJECTION)
- EPINEPHRINE 0.3 MG (EPIPEN) (INJECTION)
- EPIPEN (INTRAMUSC)
- EPIPEN JR (INTRAMUSC)

Erythropoiesis Stimulating Proteins

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- EPOGEN (INJECTION)
- RETACRIT (INJECTION)

Glucocorticoids, Inhaled

Dr. Black made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ADVAIR DISKUS (INHALATION)
- ADVAIR HFA (INHALATION)
- ASMANEX (INHALATION)
- BUDESONIDE 0.25, 0.5 MG RESPULES (INHALATION)
- BUDESONIDE 1 MG RESPULES (INHALATION)
- DULERA (INHALATION)

- FLOVENT HFA (INHALATION)
- SYMBICORT (INHALATION)

Glucocorticoids, Oral

Dr. Coleman made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- BUDESONIDE EC (ORAL)
- DEXAMETHASONE TABLET (ORAL)
- HYDROCORTISONE (ORAL)
- METHYLPREDNISOLONE TAB DS PK (ORAL)
- PREDNISOLONE SODIUM PHOSPHATE (ORAL)
- PREDNISOLONE SOLUTION (ORAL)
- PREDNISONE TABLET (ORAL)

Hemophilia Treatment

Dr. Mushatt made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ALPHANATE (INTRAVEN.)
- BENEFIX KIT (INTRAVEN.)
- COAGADEX (INTRAVEN)
- CORIFACT KIT (INTRAVEN)
- HEMLIBRA (SUBCUTANE.)
- HUMATE-P KIT (INTRAVEN.)
- JIVI (INTRAVEN)
- KOVALTRY (INTRAVEN.)
- NOVOEIGHT (INTRAVEN)
- NOVOSEVEN RT (INTRAVEN)
- NUWIQ (INTRAVEN)
- REBINYN (INTRAVEN)
- WILATE (INTRAVEN)
- XYNTHA KIT (INTRAVEN)
- XYNTHA SOLOFUSE SYRINGE KIT (INTRAVEN.)
- XYNTHA KIT (INTRAVEN)
- XYNTHA SOLOFUSE SYRINGE KIT (INTRAVEN.)

Histamine II Receptor Blockers

Dr. Figueroa made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- FAMOTIDINE SUSPENSION (ORAL)
- FAMOTIDINE TABLET (ORAL)

Idiopathic Pulmonary Fibrosis

Dr. Figueroa made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- OFEV (ORAL)
- PIRFENIDONE (ORAL)

Immune Globulins

Dr. Figueroa made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- All products in this class are recommended preferred

Immunomodulators, Asthma

Dr. Figueroa made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- FASENRA PEN (SUBCUTANEOUS)
- FASENRA SYRINGE (SUBCUTANEOUS)
- XOLAIR SYRINGE (SUB-Q)
- XOLAIR VIAL (SUB-Q)

Immunomodulators, Atopic Dermatitis

Dr. Black made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- DUPIXENT PEN (SUBCUTANEOUS)
- DUPIXENT SYRINGE (SUBCUTANEOUS)
- ELIDEL (TOPICAL)
- EUCRISA (TOPICAL)

Immunomodulators, Lupus

Dr. Coleman made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- None (all products in this class are recommended NPD)

Immunomodulators, Topical

Dr. Mushatt made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- CONDYLOX GEL (TOPICAL)
- IMIQUIMOD (ALDARA) (TOPICAL)

Intranasal Rhinitis Agents

Dr. Coleman made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- AZELASTINE (ASTELIN) (NASAL)
- AZELASTINE (ASTEPRO) (AG) (NASAL)
- AZELASTINE (ASTEPRO) (NASAL)
- FLUTICASONE (NASAL)
- IPRATROPIUM (NASAL)

Leukotriene Modifiers

Dr. Black made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- MONTELUKAST CHEWABLE TABLET (ORAL)
- MONTELUKAST TABLET (ORAL)

Methotrexate

Dr. Comeau made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- METHOTREXATE PF VIAL (INJECTION)
- METHOTREXATE TABLET (ORAL)
- METHOTREXATE VIAL (INJECTION)

Movement Disorders

Dr. Coleman made the motion to accept. Dr. Hussey seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- AUSTEDO (ORAL)
- INGREZZA (ORAL)
- INGREZZA INITIATION PACK (ORAL)
- TETRABENAZINE (ORAL)

Neuropathic Pain

Dr. Figueroa made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- DULOXETINE (CYMBALTA) (ORAL)
- GABAPENTIN CAPSULE (ORAL)
- GABAPENTIN SOLUTION (AG) (ORAL)
- GABAPENTIN SOLUTION (ORAL)
- GABAPENTIN TABLET (ORAL)
- LIDOCAINE (AG) (TOPICAL)
- LIDOCAINE (TOPICAL)
- LIDODERM (TOPICAL)
- PREGABALIN CAPSULE (AG) (ORAL)
- PREGABALIN CAPSULE (ORAL)
- PREGABALIN SOLUTION (AG) (ORAL)
- PREGABALIN SOLUTION (ORAL)
- SAVELLA (ORAL)
- SAVELLA DOSE PACK (ORAL)

NSAIDS

Dr. Mushatt made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- DICLOFENAC GEL (TOPICAL)
- DICLOFENAC SODIUM (ORAL)
- IBUPROFEN SUSPENSION (ORAL)
- IBUPROFEN TABLET (ORAL)
- INDOMETHACIN CAPSULE (ORAL)
- KETOROLAC (ORAL)
- MELOXICAM TABLET (ORAL)
- NABUMETONE (ORAL)
- NAPROXEN SUSPENSION (AG) (ORAL)
- NAPROXEN SUSPENSION (ORAL)
- NAPROXEN TABLET (ORAL)
- SULINDAC (ORAL)
- VOLTAREN (TOPICAL)

Oncology, Oral – Breast

Dr. Figueroa made the motion to accept. Dr. Hart seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ANASTROZOLE (ORAL)
- CAPECITABINE (ORAL)
- CYCLOPHOSPHAMIDE (ORAL)
- EXEMESTANE (ORAL)
- IBRANCE CAPSULE (ORAL)
- IBRANCE TABLET (ORAL)
- LETROZOLE (ORAL)
- TAMOXIFEN CITRATE (ORAL)

Oncology, Oral - Hematologic

Dr. Comeau made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- HYDROXYUREA (ORAL)
- IMATINIB (ORAL)
- IMBRUVICA CAPSULE (ORAL)
- IMBRUVICA TABLET (ORAL)
- JAKAFI (ORAL)
- LEUKERAN (ORAL)
- MERCAPTOPYRINE (ORAL)
- MYLERAN (ORAL)
- REVLIMID (ORAL)
- SPRYCEL (ORAL)
- TRETINOIN (ORAL)
- VENCLEXTA (ORAL)

- MATULANE (ORAL)
- MELPHALAN (ORAL)
- VENCLEXTA STARTING PACK (ORAL)

Oncology, Oral – Lung

Dr. Comeau made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ALECENSA (ORAL)
- GILOTRIF (ORAL)
- HYCAMTIN (ORAL)
- TAGRISSO (ORAL)
- XALKORI (ORAL)

Oncology, Oral – Other

Dr. Comeau made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- KOSELUGO (ORAL)
- TEMOZOLOMIDE (ORAL)
- ZEJULA (ORAL)

Oncology, Oral – Prostate

Dr. Black made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ABIRATERONE (ORAL)
- BICALUTAMIDE (ORAL)
- FLUTAMIDE (ORAL)
- XTANDI CAPSULE (ORAL)
- XTANDI TABLET (ORAL)

Oncology, Oral - Renal Cell

Dr. Black made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- AFINITOR (ORAL)
- EVEROLIMUS TABLET (AFINITOR) (ORAL)

- INLYTA (ORAL)
- LENVIMA (ORAL)
- NEXAVAR (ORAL)
- SORAFENIB (ORAL)
- SUNITINIB (ORAL)
- SUTENT (ORAL)
- VOTRIENT (ORAL)

Oncology, Oral – Skin

Dr. Comeau made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- COTELLIC (ORAL)
- MEKINIST (ORAL)
- ODOMZO (ORAL)
- TAFINLAR (ORAL)
- ZELBORAF (ORAL)

Ophthalmic Antibiotic/Steroid Combinations

Dr. Coleman made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- NEOMYCIN/POLYMYXIN/DEXAMETHASONE (OPHTHALMIC)
- SULFACETAMIDE / PREDNISOLONE (OPHTHALMIC)
- TOBRADEX OINTMENT (OPHTHALMIC)
- TOBRADEX SUSPENSION (OPHTHALMIC)

Ophthalmic Antibiotics

Dr. Black made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- BACITRACIN/POLYMYXIN B SULFATE OINT. (OPHTHALMIC)
- CIPROFLOXACIN SOLUTION (OPHTHALMIC)
- ERYTHROMYCIN (OPHTHALMIC)
- GENTAMICIN DROPS (OPHTHALMIC)
- GENTAMICIN OINT. (OPHTHALMIC)
- MOXIFLOXACIN (AG) (VIGAMOX) (OPHTHALMIC)
- MOXIFLOXACIN (VIGAMOX) (OPHTHALMIC)
- NEOMYCIN-POLYMYXIN-GRAMICIDIN (OPHTHALMIC)
- OFLOXACIN (OPHTHALMIC)
- POLYMYXIN/TRIMETHOPRIM (OPHTHALMIC)
- SULFACETAMIDE SOLUTION (OPHTHALMIC)
- TOBRAMYCIN DROPS (OPHTHALMIC)

Ophthalmics for Allergic Conjunctivitis

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ALREX (OPHTHALMIC)
- AZELASTINE (OPHTHALMIC)
- CROMOLYN SODIUM (OPHTHALMIC)
- OLOPATADINE (PATANOL) (OPHTHALMIC)

Ophthalmic Anti-inflammatories

Dr. Coleman made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- DEXAMETHASONE (OPHTHALMIC)
- DICLOFENAC (OPHTHALMIC)
- DIFLUPREDNATE (AG) (OPHTHALMIC)
- DIFLUPREDNATE (OPHTHALMIC)
- DUREZOL (OPHTHALMIC)
- FLUOROMETHOLONE (OPHTHALMIC)
- FLURBIPROFEN (OPHTHALMIC)
- KETOROLAC (OPHTHALMIC)
- KETOROLAC LS (OPHTHALMIC)
- PREDNISOLONE ACETATE (OPHTHALMIC)

Ophthalmics, Anti-Inflammatory/Immunomodulator

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the **PDL** are:

- RESTASIS (OPHTHALMIC)
- RESTASIS MULTIDOSE (OPHTHALMIC)
- XIIDRA (OPHTHALMIC)

OPHTHALMICS, CYSTINOSIS

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

*Recommendations for the **PDL** are:*

- None (all products in this class are recommended NPD)

Ophthalmics, Glaucoma Agents

Dr. Mushatt made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

*Recommendations for the **PDL** are:*

- | | |
|--------------------------------------|----------------------------------|
| • ALPHAGAN P 0.15% (OPHTHALMIC) | • LEVOBUNOLOL (OPHTHALMIC) |
| • BRIMONIDINE 0.2% (OPHTHALMIC) | • RHOPRESSA (OPHTHALMIC) |
| • CARTEOLOL (OPHTHALMIC) | • ROCKLATAN (OPHTHALMIC) |
| • COMBIGAN (OPHTHALMIC) | • SIMBRINZA (OPHTHALMIC) |
| • DORZOLAMIDE (OPHTHALMIC) | • TIMOLOL (OPHTHALMIC) |
| • DORZOLAMIDE / TIMOLOL (OPHTHALMIC) | • TRAVATAN Z 2.5 ML (OPHTHALMIC) |
| • LATANOPROST 2.5 ML (OPHTHALMIC) | • TRAVATAN Z 5 ML (OPHTHALMIC) |

Otic Anti-infectives & Anesthetics

Dr. Black made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

*Recommendations for the **PDL** are:*

- ACETIC ACID (OTIC)
- ACETIC ACID HC (OTIC)

Otic Antibiotics

Dr. Figueroa made the motion to accept. Dr. Hart seconded the motion. There was no objection to the motion.

*Recommendations for the **PDL** are:*

- CIPRODEX (OTIC)
- NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (AG) (OTIC)
- NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (OTIC)

- OFLOXACIN (OTIC)

Progestational Agents

Dr. Raven made the motion to accept. Dr. Hart seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- HYDROXYPROGESTERONE CAPROATE SINGLE DOSE VIAL (AG) (INTRAMUSCULAR)
- HYDROXYPROGESTERONE CAPROATE SINGLE DOSE VIAL (INTRAMUSCULAR)
- MAKENA AUTO INJECTOR (SUBCUTANEOUS)
- MEDROXYPROGESTERONE ACETATE (AG) (ORAL)
- MEDROXYPROGESTERONE ACETATE (ORAL)
- NORETHINDRONE ACETATE (ORAL)
- PROGESTERONE CAPSULE (ORAL)

Sedative Hypnotics

Dr. Hussey made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- TEMAZEPAM (AG) (ORAL)
- TEMAZEPAM (ORAL)
- TRIAZOLAM (ORAL)
- ZOLPIDEM (ORAL)

Sickle Cell Anemia Treatments

Dr. Raven made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- DROXIA (ORAL)

Smoking Cessation

Dr. Black made the motion to accept. Dr. Hart seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- BUPROPION SR (ORAL)
- CHANTIX (ORAL)
- CHANTIX DOSE PACK (ORAL)
- NICOTINE GUM OTC (BUCCAL)
- NICOTINE LOZENGE OTC (BUCCAL)
- NICOTINE PATCH OTC (TRANSDERMAL)
- VARENICLINE DOSE PACK (ORAL)
- VARENICLINE TARTRATE (ORAL)

Steroids Topical, High

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- BETAMET DIPROP / PROP GLY CREAM (TOPICAL)
- BETAMETHASONE VALERATE CREAM (TOPICAL)
- BETAMETHASONE VALERATE LOTION (TOPICAL)
- BETAMETHASONE VALERATE OINTMENT (TOPICAL)
- TRIAMCINOLONE ACETONIDE CREAM (TOPICAL)
- TRIAMCINOLONE ACETONIDE LOTION (TOPICAL)
- TRIAMCINOLONE ACETONIDE OINTMENT (TOPICAL)

Steroids Topical, Low

Dr. Figueroa made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- HYDROCORTISONE CREAM (RECTAL)
- HYDROCORTISONE CREAM (TOPICAL)
- HYDROCORTISONE LOTION (TOPICAL)
- HYDROCORTISONE OINTMENT (TOPICAL)

Steroids Topical, Medium

Dr. Black made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- FLUTICASONE PROPIONATE CREAM (TOPICAL)
- FLUTICASONE PROPIONATE OINTMENT (TOPICAL)
- MOMETASONE FUROATE CREAM (TOPICAL)
- MOMETASONE FUROATE OINTMENT (TOPICAL)
- MOMETASONE FUROATE SOLUTION (TOPICAL)

Steroids Topical, Very High

Dr. Black made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- CLOBETASOL EMOLLIENT (TOPICAL)
- CLOBETASOL PROPIONATE CREAM (TOPICAL)
- CLOBETASOL PROPIONATE GEL (TOPICAL)

- CLOBETASOL PROPIONATE OINTMENT (TOPICAL)
- CLOBETASOL PROPIONATE SOLUTION (TOPICAL)
- HALOBETASOL PROPIONATE CREAM (TOPICAL)
- HALOBETASOL PROPIONATE OINTMENT (TOPICAL)

Stimulants and Related Agents

Dr. Hussey made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ADDERALL XR (ORAL)
- AMPHETAMINE SALT COMBO (ORAL)
- ATOMOXETINE (AG) (ORAL)
- ATOMOXETINE (ORAL)
- DEXMETHYLPHENIDATE (ORAL)
- DEXMETHYLPHENIDATE ER (AG) (ORAL)
- DEXMETHYLPHENIDATE ER (ORAL)
- DEXTROAMPHETAMINE TABLET (ORAL)
- GUANFACINE ER (ORAL)
- METHYLPHENIDATE (ORAL)
- METHYLPHENIDATE CD (AG) (ORAL)
- METHYLPHENIDATE CD (ORAL)
- METHYLPHENIDATE ER (CONCERTA) (AG) (ORAL)
- METHYLPHENIDATE ER (CONCERTA) (ORAL)
- METHYLPHENIDATE ER (RITALIN LA) (ORAL)
- METHYLPHENIDATE SOLUTION (ORAL)
- MODAFINIL (ORAL)
- QUILLICHEW ER (ORAL)
- QUILLIVANT XR (ORAL)
- VYVANSE CAPSULE (ORAL)
- VYVANSE CHEWABLE TABLET (ORAL)

Thrombopoiesis Stimulating Proteins

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- PROMACTA TABLET (ORAL)

II. Single Drug Reviews

In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing	Drug/Issue
Abdul Khan	North Oaks Medical Center	Mounjaro
**NOTE: Names of speakers who were present and yielded their time back were not captured.		

Antibiotics, Vaginal

Dr. Figueroa made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

- XACIATO (VAGINAL) – recommended NPD

Antifungals, Oral

Dr. Raven made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

- VIVJOA CAPSULE (ORAL) - recommended NPD

Calcium Channel Blockers

Dr. Black made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

- NORLIQVA - recommended NPD

GI Motility, Chronic

Dr. Black made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

- IBSRELA (ORAL) – recommended NPD

HIV / AIDS

Dr. Figueroa made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

- TRIUMEQ PD TAB SUSP (ORAL) – recommended preferred

Hypoglycemics, Incretin Mimetics/Enhancers

Dr. Coleman made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

- MOUNJARO (SUBCUTANE.) – recommended NPD

Multiple Sclerosis Agents

Dr. Raven made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

- TASCENSO ODT (ORAL) - recommended NPD

PAH Agents, Oral And Inhaled

Dr. Figueroa made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

- TYVASO DPI (INHALATION) - recommended NPD

Pituitary Suppressive Agents, LHRH

Dr. Mushatt made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

- CAMCEVI (SUBCUTANEOUS) - recommended NPD

Skeletal Muscle Relaxants

Dr. Black made the motion to accept. Dr. Hart seconded the motion. There was no objection to the motion.

- LYVISPAH (ORAL) - recommended NPD

Other Business

Dr. Wendt thanked the committee members for their attendance today.

Next Steps

- A. Proposed Therapeutic Classes to be Reviewed at Next Meeting.** Dr. Douiki presented the list of therapeutic classes to be reviewed at the spring 2023 P&T meeting.
- B. Next Meeting Date.** The next committee meeting is scheduled for May 5, 2023.
- C. Public Testimony.** None.

Adjournment

Dr. Figueroa made the motion to adjourn. Dr. Coleman seconded the motion. The meeting adjourned at or about 11:45 a.m.

Ben Orlando
Chairman P&T Committee

Date